Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023 07:00 ET
|
Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023 07:00 ET
|
Optinose, Inc.
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 ...
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 16:08 ET
|
Optinose, Inc.
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose to Present at the Jefferies Healthcare Conference
June 02, 2023 13:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 11, 2023 07:00 ET
|
Optinose, Inc.
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company...
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023 07:00 ET
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
May 01, 2023 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2023 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2023 16:00 ET
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians...